Schizophrenia Products and Drug Pipeline Review, H1 2015

Schizophrenia - Pipeline Review, H1 2015 provides an overview of the Schizophrenia's therapeutic pipeline. This report is now available at

This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

Some of the Company profiles mentioned in this report are BCWorld Pharm Co. Ltd., Critical Pharmaceuticals Limited, Dong Wha Pharma Co., Ltd., FORUM Pharmaceuticals Inc., Genovate Biotechnology Co., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co., Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Nhwa Pharma Corporation, Karuna Pharmaceuticals Inc., Lohocla Research Corporation, Neurocrine Biosciences, Inc., Promentis Pharmaceuticals, SK Biopharmaceuticals Co., Ltd., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited.

Get a copy of this report at . (This is a premium report price at US$2000 for a single user PDF license)


- The report provides a snapshot of the global therapeutic landscape of Schizophrenia

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

This report helps to Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage, Develop strategic initiatives by understanding the focus areas of leading companies and Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.